Before a bronchoscopy, the nurse's priority is to identify any risk factors that could lead to life-threatening complications during or after the procedure. While all the listed findings require attention, one represents an absolute contraindication due to the risk of uncontrolled bleeding. The procedure involves passing a scope into the airways, and often includes a biopsy, which causes tissue trauma. The body's ability to form a clot is therefore critical.
The most critical finding to report is a platelet count of 75,000 per cubic millimeter. This represents significant thrombocytopenia. A normal platelet count is typically between 150,000 and 400,000 per cubic millimeter. A level below 100,000, and especially below 80,000, dramatically increases the risk of spontaneous and procedure-induced bleeding. During a bronchoscopy, even minor trauma from the scope or a biopsy can lead to a hemorrhage in the airways that is difficult to control and can quickly compromise the patient's airway and ventilation. The risk of bleeding is a primary concern in transbronchial procedures, as highlighted by the need for careful patient selection to minimize complications in lung biopsy techniques [1]. Reporting this before the procedure allows the provider to consider a platelet transfusion or cancel the procedure to prevent a catastrophic bleeding event.
The other findings, while not normal, are less immediately dangerous in the context of a contraindication. A blood pressure of 150/88 mmHg (Option 1) indicates Stage 1 hypertension. While it should be reported, it is not an absolute contraindication and can often be managed with pre-procedural medication. A heart rate of 102 beats per minute (Option 3) is mild sinus tachycardia, which could be due to anxiety, pain, or dehydration. It warrants investigation but does not pose the same immediate procedural threat as a bleeding diathesis. An oxygen saturation of 94% on room air (Option 4) is a mild hypoxemia that is expected in many patients with pulmonary disease requiring bronchoscopy. It is a key part of the assessment but is managed with supplemental oxygen during the procedure, not a reason to halt it. The foundational principle is that the risk of a fatal procedural complication, such as an airway hemorrhage, outweighs other concerns. A review of fatal adverse events related to procedural sedation and analgesia underscores that major complications, though rare, are often cardiorespiratory in nature, and a pre-existing bleeding risk is a direct setup for such a crisis .
A platelet count below 100,000/mm³ is a major red flag. A value of 75,000/mm³ represents severe thrombocytopenia and is often considered an absolute contraindication for transbronchial biopsy due to the risk of catastrophic airway hemorrhage.
The primary safety concern is uncontrolled bleeding. Even minor scope trauma or a biopsy can trigger hemorrhage that compromises the airway. Always verify coagulation studies (platelets, PT/INR, PTT) before the procedure.
Do not proceed with biopsy if platelets are critically low without a corrective action plan. The provider may order a platelet transfusion immediately pre-procedure or cancel the bronchoscopy to prevent a life-threatening event.
학습 참고용입니다. 실제 임상은 최신 지침과 소속 기관 프로토콜을 따르세요.